Navigation Links
WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
Date:7/10/2008

SHANGHAI, China, July 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Dr. Debra Yu as the Vice President of Strategy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi PharmaTech, Dr. Yu worked at Pfizer Inc., where she co-led Pfizer's venture capital group and was instrumental in working in diverse areas such as diagnostics, asset monetization and creative finance structures and Pfizer's innovation agenda. Earlier she was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two leading Bay area venture firms focused on the life sciences. In addition, Dr. Yu has held senior positions at many leading companies and organizations like McKinsey & Co., the U.S. Food and Drug Administration (FDA), the Wilkerson Group, Morgan Stanley & Co., Genentech Inc. and the Permanente Company. She has stewarded more than 25 companies through venture capital, and sat on the board of eight and stepped in as Chief Executive Officer of one.

Dr. Yu's responsibilities in her new role include bringing constructive leadership and stewardship to the company's strategic planning and initiatives. Dr. Yu will report directly to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

"I am very pleased to welcome Debra on board to further increase the depth of our senior management," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "With 19 years of experiences in venture capital and life sciences, Debra will provide strategic guidance as we continue building a global drug and medical device R&D service platform through organic growth, partnership and M&A."

Dr. Yu received he
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... May 23, 2013  Verenium Corporation (Nasdaq: ... the development and commercialization of high-performance enzymes, today announced ... Officer, will present at two upcoming conferences. ... present at the Second Annual Marcum LLP Microcap Conference ... Hotel in New York City.  The presentation is scheduled ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...
(Date:5/23/2013)... Bed bugs compromised Penn State. ... confirmed it. Meanwhile, My Cleaning Products offered complimentary samples of ... the pests without using harmful chemical elements. , Based ... the affected building was actually a dormitory , My ... made on May 13 and bed bug presence was confirmed ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... REDWOOD CITY, Calif., Feb. 1, 2012 Codexis, Inc. ... enzymes to enable affordable and abundant sugar for the ... company will be participating in the following upcoming investor ... 2012Time: , 10:00 a.m. PT (Panel: The Rise of ...
... 2012 Alchem International Ltd. opens its ... marketing office will be spearheaded by Laurent Leduc, former ... cater to the rapidly growing demand in North America ... for the supplement, pharmaceutical and cosmetic industries. ...
... BOSTON and SEOUL, Korea, Feb. 1, 2012   PAREXEL ... leading global biopharmaceutical services provider, announced today that it ... Center (AMC), based in Seoul, Korea. The alliance ... access to high quality clinical trial services throughout ...
Cached Biology Technology:Alchem International Opens Sales and Marketing Office in the U.S. 2PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 2PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 3PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 4PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 5
(Date:5/23/2013)... new mechanism by which estrogen suppresses lipid synthesis in ... new approach toward treating certain liver diseases. , ... they are changing long-held views in the field. Study ... journal Science Signaling . , "The dogma in ... that only receptors located in the nucleus respond to ...
(Date:5/23/2013)... WASHINGTON Given the implications for the overall ... should play a primary role in ensuring that ... least 60 minutes per day of vigorous or ... the Institute of Medicine. Recent estimates suggest ... this evidence-based guideline for promoting better health and ...
(Date:5/23/2013)... 2013) A new report from the Institute of ... engage in at least 60 minutes of vigorous or ... more than half of American youth meet current evidence-based ... moderate intensity physical activity daily, according to the report, ... in school for nearly half of their waking hours, ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Schools should provide students with daily physical activity, IOM recommends 2
... have appeared as being in perpetual conflict, but a new ... scientists at major research universities see religion and science as ... the meaning of life, ways of understanding reality, origins of ... religion and science as being at odds and even in ...
... is the body,s armor, protecting us from disease agents, injury, ... a single gene, the gene for the protein p63, cause ... the epidermis and other tissues. In the epidermis, ... bleeding, infection, and discoloration. A research team from ...
... University of Massachusetts Amherst environmental toxicologist Edward Calabrese, ... chemicals and radiation are benign or even helpful, says ... of radiation genetics, Nobel Prize winner Hermann Muller, knowingly ... no safe level of radiation exposure. Calabrese,s ...
Cached Biology News:Science and religion do mix 2Science and religion do mix 3How key genes cooperate to make healthy skin 2How key genes cooperate to make healthy skin 3How key genes cooperate to make healthy skin 4UMass researcher points to suppression of evidence on radiation effects by 1946 Nobel Laureate 2UMass researcher points to suppression of evidence on radiation effects by 1946 Nobel Laureate 3
Human Cystatin F MAb (Clone 292103)...
... is an inhibitor of ... concentration of inhibitor required ... must be determined empirically ... micromolar inhibitor is sufficient ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
Biology Products: